Investigating causes of heterogeneity in systematic reviews

被引:149
作者
Glasziou, PP
Sanders, SL
机构
[1] Univ Queensland, Ctr Evidence Based Hlth Ctr, Brisbane, Qld, Australia
[2] Univ Queensland, Ctr Gen Practice, Brisbane, Qld, Australia
关键词
heterogeneity; systematic review; meta analysis; effect modification; interaction;
D O I
10.1002/sim.1183
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
What causes heterogeneity in systematic reviews of controlled trials? First, it may be an artefact of the summary measures used, of study design features such as duration of follow-up or the reliability of outcome measures. Second, it may be due to real variation in the treatment effect and hence provides the opportunity to identify factors that may modify the impact of treatment. These factors may include features of the population such as: severity of illness, age and gender; intervention factors such as dose, timing or duration of treatment; and comparator factors such as the control group treatment or the co-interventions in both groups. The ideal way to study causes of true variation is within rather than between studies. In most situations however, we will have to make do with a study level investigation and hence need to be careful about adjusting for potential confounding by artefactual factors such as study design features. Such investigation of artefactual and true causes of heterogeneity form essential steps in moving from a combined effect estimate to application to particular populations and individuals. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:1503 / 1511
页数:9
相关论文
共 25 条
  • [1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [2] INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS
    APPLEBY, P
    BAIGENT, C
    COLLINS, R
    FLATHER, M
    PARISH, S
    PETO, R
    BELL, P
    HALLS, H
    MEAD, G
    DIAZ, R
    PAOLASSO, E
    PAVIOTTI, C
    ROMERO, G
    CAMPBELL, T
    OROURKE, MF
    THOMPSON, P
    LESAFFRE, E
    VANDEWERF, F
    VERSTRAETE, M
    ARMSTRONG, PW
    CAIRNS, JA
    MORAN, C
    TURPIE, AG
    YUSUF, S
    GRANDE, P
    HEIKKILA, J
    KALA, R
    BASSAND, JP
    BOISSEL, JP
    BROCHIER, M
    LEIZOROVICZ, A
    BRUGGEMANN, T
    KARSCH, KR
    KASPER, W
    LAMMERTS, D
    NEUHAUS, KL
    MEYER, J
    SCHRODER, R
    VONESSEN, R
    SARAN, RK
    ARDISSINO, D
    BONADUCE, D
    BRUNELLI, C
    CERNIGLIARO, C
    FORESTI, A
    FRANZOSI, MG
    GUIDUCCI, D
    MAGGIONI, A
    MAGNANI, B
    MATTIOLI, G
    [J]. LANCET, 1994, 343 (8893) : 311 - 322
  • [3] Menstrual cycle variation in mammographic breast density: So who cares?
    Baines, CJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (12): : 875 - 876
  • [4] BERLIN J, STAT MED, V21, P101
  • [5] INVITED COMMENTARY - BENEFITS OF HETEROGENEITY IN METAANALYSIS OF DATA FROM EPIDEMIOLOGIC STUDIES
    BERLIN, JA
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (04) : 383 - 387
  • [6] CLASZIOU PP, 2000, ANTIBIOTICS ACUTE OT
  • [7] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT
    COLLINS, R
    PETO, R
    MACMAHON, S
    HEBERT, P
    FIEBACH, NH
    EBERLEIN, KA
    GODWIN, J
    QIZILBASH, N
    TAYLOR, JO
    HENNEKENS, CH
    [J]. LANCET, 1990, 335 (8693) : 827 - 838
  • [8] Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes
    Deeks, JJ
    [J]. STATISTICS IN MEDICINE, 2002, 21 (11) : 1575 - 1600
  • [9] EDWARDS JE, 2000, SINGLE DOSE ORAL ASP
  • [10] AN EVIDENCE BASED APPROACH TO INDIVIDUALIZING TREATMENT
    GLASZIOU, PP
    IRWIG, LM
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1995, 311 (7016): : 1356 - 1359